See more : Hyundai Motor Company (005389.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Supernus Pharmaceuticals, Inc. (0LB2.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Supernus Pharmaceuticals, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Sildarvinnslan Hf. (SVN.IC) Income Statement Analysis – Financial Results
- OSAKA Titanium technologies Co.,Ltd. (5726.T) Income Statement Analysis – Financial Results
- Nomura Holdings, Inc. (NRSCF) Income Statement Analysis – Financial Results
- S&U plc (47IE.L) Income Statement Analysis – Financial Results
- Challenger Energy Group PLC (BSHPF) Income Statement Analysis – Financial Results
Supernus Pharmaceuticals, Inc. (0LB2.L)
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 607.52M | 667.24M | 579.78M | 520.40M | 392.76M | 408.90M | 302.24M | 215.00M | 144.43M | 122.05M | 12.02M | 1.48M | 803.00K | 106.00K | 37.93M | 8.89M | 4.23M |
| Cost of Revenue | 83.78M | 87.22M | 75.06M | 52.46M | 16.66M | 15.36M | 15.22M | 11.99M | 8.42M | 5.76M | 1.10M | 0.00 | 0.00 | -13.40M | -8.59M | 336.00 | 0.00 |
| Gross Profit | 523.74M | 580.02M | 504.71M | 467.94M | 376.10M | 393.54M | 287.02M | 203.02M | 136.00M | 116.29M | 10.92M | 1.48M | 803.00K | 13.51M | 46.51M | 8.89M | 4.23M |
| Gross Profit Ratio | 86.21% | 86.93% | 87.05% | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% | 94.17% | 95.28% | 90.81% | 100.00% | 100.00% | 12,745.28% | 122.65% | 100.00% | 100.00% |
| Research & Development | 91.59M | 74.55M | 90.47M | 75.96M | 69.10M | 89.21M | 49.58M | 42.79M | 29.14M | 19.59M | 17.25M | 23.52M | 30.63M | 35.15M | 29.26M | 30.46M | 19.27M |
| General & Administrative | 236.66M | 109.43M | 105.05M | 65.92M | 117.63M | 116.59M | 104.11M | 84.11M | 69.90M | 57.67M | 40.99M | 14.33M | 0.00 | 5.08M | 4.65M | 4.29M | 0.00 |
| Selling & Marketing | 99.70M | 267.79M | 199.71M | 134.75M | 40.80M | 43.30M | 33.80M | 21.90M | 19.30M | 14.80M | 14.60M | 5.80M | 0.00 | 0.00 | 94.00 | 499.00 | 0.00 |
| SG&A | 336.36M | 377.22M | 304.76M | 200.68M | 158.43M | 159.89M | 137.91M | 106.01M | 89.20M | 72.47M | 55.59M | 20.13M | 7.93M | 5.08M | 4.65M | 4.29M | 4.01M |
| Other Expenses | 101.06M | 82.63M | 29.99M | 15.70M | 0.00 | 0.00 | 0.00 | -15.00K | 38.00K | 39.00K | 101.00K | -660.00K | 117.00K | 542.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 529.01M | 534.40M | 425.22M | 292.34M | 227.52M | 249.10M | 187.48M | 148.80M | 118.34M | 92.06M | 72.84M | 43.65M | 38.56M | 40.23M | 33.91M | 34.75M | 23.28M |
| Cost & Expenses | 612.79M | 621.62M | 500.28M | 344.80M | 244.18M | 264.45M | 202.70M | 160.79M | 126.76M | 97.82M | 73.94M | 43.65M | 38.56M | 40.23M | 33.91M | 34.75M | 23.28M |
| Interest Income | 10.45M | 21.69M | 10.57M | 18.70M | 21.62M | 13.84M | 2.86M | 1.48M | 643.00K | 387.00K | 400.00K | 120.00K | 31.00K | 107.00K | 122.00K | 1.06M | 1.77M |
| Interest Expense | 2.42M | 7.07M | 23.42M | 23.75M | 22.71M | 18.11M | 1.57M | 5.09M | 1.23M | 4.96M | 7.85M | 3.58M | 1.87M | 107.00K | 122.00K | 8.68M | 1.77M |
| Depreciation & Amortization | 84.86M | 85.63M | 32.59M | 20.00M | 10.23M | 7.06M | 8.13M | 2.40M | 921.00K | 928.00K | 742.00K | 871.00K | 879.00K | 1.19M | 1.07M | 1.12M | 932.21K |
| EBITDA | 90.04M | 153.44M | 129.19M | 212.40M | 180.42M | 151.51M | 107.67M | 56.62M | 21.77M | -4.35M | -83.68M | -41.84M | -36.73M | -38.29M | 5.21M | -23.69M | -16.34M |
| EBITDA Ratio | 14.82% | 22.47% | 20.71% | 40.35% | 43.33% | 38.71% | 33.88% | 25.90% | 12.70% | 20.17% | -511.86% | -2,885.74% | -4,573.47% | -36,118.87% | 13.74% | -266.50% | -386.02% |
| Operating Income | -5.27M | 67.30M | 86.03M | 173.70M | 148.57M | 144.44M | 99.54M | 54.22M | 17.67M | 24.23M | -61.92M | -42.17M | -37.75M | -40.12M | 4.02M | -25.86M | -19.05M |
| Operating Income Ratio | -0.87% | 10.09% | 14.84% | 33.38% | 37.83% | 35.33% | 32.93% | 25.22% | 12.23% | 19.85% | -515.18% | -2,849.26% | -4,701.37% | -37,851.89% | 10.59% | -290.93% | -449.92% |
| Total Other Income/Expenses | 8.04M | 14.62M | -12.85M | -5.05M | -1.08M | -4.27M | 1.08M | -3.85M | -6.23M | -4.36M | -30.35M | -4.12M | -1.72M | 649.00K | 122.00K | -7.62M | 1.77M |
| Income Before Tax | 2.77M | 60.74M | 73.18M | 168.65M | 147.49M | 140.18M | 100.62M | 50.37M | 14.97M | 19.87M | -92.27M | -46.28M | -39.47M | -39.47M | 4.14M | -33.48M | -17.27M |
| Income Before Tax Ratio | 0.46% | 9.10% | 12.62% | 32.41% | 37.55% | 34.28% | 33.29% | 23.43% | 10.37% | 16.28% | -767.73% | -3,127.30% | -4,915.32% | -37,239.62% | 10.91% | -376.67% | -408.04% |
| Income Tax Expense | 1.45M | 32.00K | 19.75M | 41.70M | 34.43M | 29.18M | 43.33M | -40.85M | 956.00K | 4.04M | 7.11M | 1.14M | -16.25M | -399.00K | 3.80M | 1.06M | 1.77M |
| Net Income | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M | 14.02M | 19.87M | -92.27M | -46.28M | 56.00M | -38.46M | 460.00K | -33.48M | -17.27M |
| Net Income Ratio | 0.22% | 9.10% | 9.21% | 24.39% | 28.79% | 27.14% | 18.95% | 42.43% | 9.70% | 16.28% | -767.73% | -3,127.30% | 6,974.22% | -36,285.85% | 1.21% | -376.67% | -408.04% |
| EPS | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | 0.47 | -2.90 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| EPS Diluted | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 | 0.28 | 0.32 | -2.90 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| Weighted Avg Shares Out | 54.54M | 53.67M | 53.10M | 52.62M | 52.41M | 51.99M | 50.76M | 49.47M | 47.49M | 42.26M | 31.82M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M | 13.86M |
| Weighted Avg Shares Out (Dil) | 55.51M | 61.68M | 54.36M | 53.69M | 53.82M | 54.10M | 53.30M | 51.71M | 51.16M | 50.58M | 31.85M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M | 13.86M |
Source: https://incomestatements.info
Category: Stock Reports